Stay updated on SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision history updated to include v3.3.4 and remove v3.3.3 for the study NCT04293276.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedThe page history now shows a new revision (v3.3.3); the HHS Vulnerability Disclosure link and the older revision (v3.3.2) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check58 days agoChange DetectedThe Record History now shows a new revision: v3.3.2, replacing the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check66 days agoChange DetectedRemoved the generic government funding/operating status notice at the top of the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check80 days agoChange DetectedVersion history shows updates to Recruitment Status and Study Status across several releases, reflecting changes in the trial’s enrollment and activity. The most recent version (2023-05-03) includes changes to Recruitment Status and Study Status.SummaryDifference0.1%

- Check109 days agoChange DetectedMajor change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).SummaryDifference13%

Stay in the know with updates to SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.